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ndothelial Progenitors
New Tower of Babel?*
onathan Leor, MD, FACC,†
ichael Marber, MD, FACC‡
el-Hashomer, Israel;
nd London, United Kingdom
ne of the most fascinating breakthroughs in the field of
ascular biology in the last decade was the discovery of
ndothelial progenitor cells (EPCs) (1). These angiogenic
ells, with properties of embryonal angioblasts, are bone
arrow residents, and mobilize in response to various
timuli (2). Endothelial progenitor cells may contribute to
he maintenance of the vasculature and to the remodeling
hat accompanies new vessel growth with ischemia. Reflect-
See page 1579
ng their proposed sentinel function, the number of circu-
ating EPCs has been suggested to mirror vascular health
nd to represent a marker by which to assess cardiovascular
isease risk (3–6). However, despite extensive research
ctivity, surprisingly, there is no accepted standard method
r criteria for defining an EPC. The lack of a uniform EPC
efinition complicates cross-study comparisons and may
ontribute to the apparent paradox of some studies suggest-
ng that EPCs are reduced in the presence of cardiovascular
isk factors and coronary artery disease (CAD) (4,6–10),
hereas others suggest that numbers are increased in those
ith obstructive CAD (11,12).
HO’S THAT CELL? EPC NOMENCLATURE
n the hierarchy established in the hematopoietic system,
rogenitors identify cells with lower differentiation potential
han stem cells. However, EPCs possess degrees of “stem-
ess”, which include self-renewal, clonogenicity, and differ-
ntiation capacity (13,14). Circulating EPCs were initially
dentified through their expression of CD34 (a surface
arker common to hematopoietic stem cells and mature
ndothelial cells) and vascular endothelial cell growth factor
eceptor 2 (VEGFR2 or kinase-domain–related [KDR]
eceptor), but not of other markers seen on fully differen-
iated endothelial cells (1). Subsequent studies have incor-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ell therapy for Gamida Cell Ltd.orated other markers, such as the stem-cell marker
D133, which is not expressed by more differentiated cells.
ther methods of characterization are based on in vitro
ehavior, including the ability to form endothelial
olonies—colony-forming units (CFUs)—with the incor-
oration of acetylated low-density lipoprotein and binding
f lectins (6). However, endothelial progenitor cells defined
n these ways probably represent a mixed population, which,
n combination with the lack of a consensual definition,
ake the interpretation and comparison of works in this
eld impossible. The current chaotic situation was high-
ighted by George et al. (15), who found that in healthy
ndividuals there was no correlation between the various
ethods used for estimating EPC numbers.
In vitro studies have suggested that at least 2 populations of
PCs exist. “Early EPCs” (4 days), also called circulating
ngiogenic cells (CACs), are monocyte derived, are capable of
ssuming endothelial features, and produce angiogenic cyto-
ines (2). The “true” endothelial precursor cell population,
apable of generating late outgrowth of endothelial cells, are
are within the circulation (0.01%), appear later (14 to 21
ays) in culture, and likely originate from a subset of CD14/
D34/KDR cells that are not fully defined (2). However,
he exact phenotypic characterization still remains unclear, and
efinitions should be made with caution.
PCS AND CAD: POSITIVE
R NEGATIVE RELATIONSHIP?
everal physiologic stimuli, disease states, and drugs have
een shown to influence EPC number and function (2).
lthough growing evidence suggests that circulating EPCs
re depleted and exhausted in the presence of atherosclerosis
isk factors (7–10), reports on circulating EPC number and
AD fail to show agreement. Several investigators report
evels to be lower in disease states, although some have
ound increased EPCs in more severe disease. Vasa et al.
16) reported lower numbers of EPCs in patients with CAD
ompared with healthy controls, and the numbers of EPCs
orrelated inversely with the number of risk factors. Adams
t al. (17) also reported somewhat lower EPC numbers in
atients with CAD than in healthy controls, whereas
xercise resulted in a transient increase. George et al. (11)
eported higher EPCs in patients with unstable, compared
ith stable, angina as well as a positive correlation between
PC colony-forming units and the inflammatory marker
RP. Others found increased EPCs in acute myocardial
nfarction and chronic stable angina compared with controls
18,19), as well as after coronary bypass surgery (7). Lam-
iase et al. (12) have shown that poor coronary collateral
evelopment is associated with reduced numbers of circu-
ating EPCs. However, they also found that patients with
igh collateral flow indices had more severe coronary
tenoses and likely more severe myocardial ischemia. It was
hus difficult to be certain whether EPCs relate to collaterals
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October 17, 2006:1588–90 Editorial Commentr ischemia. Moreover, circulating EPCs may contribute to
rogression of atherosclerosis, as shown in animal models
nd transplant atherosclerosis (20–22).
Despite their complexities, the popular concept is that
irculating EPCs are protective, and their lack mirrors and
redicts disease progression and future cardiovascular
vents. Very recent studies by Werner et al. (3) and
chmidt-Lucke et al. (5) have shown that reduced numbers
f circulating CD34/KDR EPCs predict the occurrence
f cardiovascular events and death.
HE PRESENT STUDY RAISES MORE QUESTIONS
n this issue of the Journal, Güven et al. (23) have attempted
o carefully address the relationship between circulating
PCs and CAD. They used an in vitro assay adopted from
ngram et al. (14) to measure the number of EPCs and
ACs grown from blood samples of 48 patients undergoing
oronary angiography. Patients with acute coronary syn-
romes were excluded. Their definition of EPCs was cells
hat eventually formed colonies of mature endothelial cells
fter 14 to 28 days in culture. In contrast to several previous
eports, the number of EPC and CAC colonies was in-
reased in proportion with the severity of CAD. In addition,
n the population studied, and in contrast to previous
eports, the level of EPCs did not vary significantly with
ge, cardiovascular risk factors, or CRP level. Thus, the
tudy raises more questions about the value of EPCs as a
alid diagnostic and prognostic tool.
The methodology of the present study is different from
any others. An in vitro assay was used and “true” EPCs
ere identified by the formation of discrete colonies of
ndothelial cells on days 14 to 28 of culture. Many previous
eports assess colony number earlier (7 days) and/or measure
urface antigen expression by flow activated cell sorter. The
se of an in vitro assay in isolation may be affected by culture
onditions such as efficiency of adhesion to plastic ware,
roliferation, and survival in culture (15). Endothelial cells
ultured from peripheral blood do not directly correspond to
he actual population of circulating EPCs because they may
nclude other circulating cells with an endothelial cell
henotype. Taken together, the results of the present study,
lthough provocative, do not provide a definitive answer to
he question: what is the relationship between EPCs and
AD? The uncertainty is the result of using diverse meth-
dologies to identify EPCs.
E NEED A STANDARD BY WHICH TO DEFINE EPCS
ariations in methodology have created confusion regarding
he interpretation of EPC findings across studies. Consid-
ring the growing evidence in support of circulating EPCs
s a marker (positive or negative) of vascular health, it would
e helpful to define standards to identify these cells. With so
any uncertainties, what is the “take home message” of the
resent study by Güven et al. (23)? In our view, this study
ighlights the potential shortcomings of attempting trans-ational studies before understanding the pathophysiological
ole of endogenous EPCs. Furthermore, it illustrates that we,
s a research community, still do not even have a standardized
nd accepted method by which to assess circulating EPCs.
ithout such a method, comparisons across studies are com-
lex and differences often are irreconcilable. This lack of
ethodological consensus denies us a shared language, without
hich we are in danger of continuing to build a scientific
tructure with the fragility of the Tower of Babel!
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